5.85
0.68%
-0.04
Handel nachbörslich:
5.88
0.03
+0.51%
Mind Medicine Inc Aktie (MNMD) Neueste Nachrichten
MindMed executive sells over $26k in company stock By Investing.com - Investing.com Australia
MindMed CEO Robert Barrow sells shares worth over $118,000 - Investing.com
MindMed executive sells shares worth over $14k - Investing.com India
MindMed CEO Robert Barrow sells shares worth over $118,000 By Investing.com - Investing.com UK
Generalized Anxiety Disorder Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, MOA, ROA by DelveInsight | Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, MindMed, VistaGen Pharma - Barchart
Rhumbline Advisers Invests $679,000 in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
Generalized Anxiety Disorder Global Market is Booming Across - openPR
(MNMD) Proactive Strategies - Stock Traders Daily
Mankind Pharma: Rs 10000 crore fund raise via this routeDetails - ET Now
Mankind Pharma to raise up to ₹10,000 crore through NCDs - CNBCTV18
Mankind Pharma board approves up to Rs 10,000-crore fund raise via NCDs, CPs - Moneycontrol
Mount Sinai Opens New Psychedelic Research Center in NYC - Mirage News
Psychedelic research at a crossroads - Science
Director GRYSKA DAVID W acquired 3,500 shares of Mind Medicine Inc [MNMD] - Knox Daily
Bank of New York Mellon Corp Buys 203,216 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
Wall Street analysts’ outlook for Mind Medicine Inc (MNMD) - SETE News
Examining the Potential Price Growth of Mind Medicine Inc (MNMD) - Knox Daily
Long Strange Trip Continues for Psychedelics in PTSD, TRD - Managed Healthcare Executive
A closer look at Mind Medicine Inc (MNMD)’s stock price trends - US Post News
Mind Medicine (MindMed) (NASDAQ:MNMD) Given New $14.00 Price Target at Canaccord Genuity Group - Defense World
Mannkind Corp (MNKD) gets rating Resumed from Leerink Partners - Knox Daily
Mind Medicine (MindMed) (NASDAQ:MNMD) PT Lowered to $14.00 at Canaccord Genuity Group - MarketBeat
Trend Tracker for (MNMD) - Stock Traders Daily
MindMed Issues New Employee Share Options - TipRanks
MindMed Announces New Employee Inducement Grants - Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Average Rating of "Buy" by Analysts - MarketBeat
MindMed Showcases Innovation at Investor Events - TipRanks
MindMed to Participate in September Investor Conferences - StockTitan
MindMed to Participate in September Investor Conferences - Yahoo Finance
Mind Medicine (MindMed) Inc. Expected to Earn Q3 2024 Earnings of ($0.27) Per Share (NASDAQ:MNMD) - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Price Target Raised to $55.00 - MarketBeat
(MNMD) Long Term Investment Analysis - Stock Traders Daily
Mind medicine director David Gryska buys $20,930 in company shares By Investing.com - Investing.com Canada
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Director Acquires $20,930.00 in Stock - MarketBeat
Mind medicine director David Gryska buys $20,930 in company shares By Investing.com - Investing.com Australia
Mind medicine director David Gryska buys $20,930 in company shares - Investing.com India
Mind medicine director David Gryska buys $20,930 in company shares - Investing.com
Mind medicine director David Gryska buys $20,930 in company shares By Investing.com - Investing.com UK
Mind Medicine Inc’s $75 Million Common Shares Offering - Global Legal Chronicle
Mind Medicine: Pumping Up The Balance Sheet (Again) (NASDAQ:MNMD) - Seeking Alpha
Mind Medicine CEO Robert Barrow buys $6,215 in shares - Investing.com India
Mind Medicine CEO Robert Barrow buys $6,215 in shares - Investing.com
Mind Medicine CEO Robert Barrow buys $6,215 in shares By Investing.com - Investing.com UK
Mind Medicine Highlights GAD’s Economic Impact - TipRanks
MindMed to Showcase at Neuro Conference - TipRanks
MindMed to Engage in Canaccord Genuity Growth Event - TipRanks
MindMed to Present at Oppenheimer Healthcare Conference - TipRanks
MindMed Unveils GAD Treatment Study at Key Conferences - TipRanks
MNMD (Mind Medicine) EV-to-Revenue : (As of Aug. 19, 2024) - GuruFocus.com
Vanguard Group Inc. Reduces Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World
Mind Medicine (NEOE:MMED) Cash-to-Debt : 10.03 (As of Jun. 2024) - GuruFocus.com
MNMD (Mind Medicine) Intrinsic Value: DCF (Earnings Based) : $-24.41 (As of Aug. 16, 2024) - GuruFocus.com
Brokers Issue Forecasts for Mind Medicine (MindMed) Inc.'s Q3 2024 Earnings (NASDAQ:MNMD) - MarketBeat
Q3 2024 Earnings Estimate for Mind Medicine (MindMed) Inc. Issued By Leerink Partnrs (NASDAQ:MNMD) - Defense World
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Forecasted to Post Q3 2024 Earnings of ($0.31) Per Share - Defense World
Psychedelic Stocks: Focus On Their Cash - Seeking Alpha
Hogan Lovells Guides Mind Medicine Inc. on its US$75m Underwritten Public Offering - Legal Desire News Network
Small Cap Stocks: Mind Medicine (MNMD) Is a Psychedelic Biotechnology Bet - Nasdaq
Mind Medicine (MindMed) (OTCMKTS:MMEDF) Stock Price Down 3.8% - Defense World
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap Up to $6.85 - MarketBeat
MindMed Reports Second Quarter 2024 Financial Results and Business Updates - citybiz
MNMD Stock Earnings: Mind Medicine Misses EPS for Q2 2024 - InvestorPlace
MindMed Advances MM120 Trials with Strong Finances - TipRanks
MindMed reassures investors with its cash cushion for drug studies - Green Market Report
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering - Manchestertimes
MindMed Reports Second Quarter 2024 Financial Results and Business Updates - Business Wire
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):